Annoucing the 2025 HBA Global Board of Directors
At this week's Annual Business Meeting (ABM), the HBA announced the results of the recent member voting on the 2025 Global Board of Directors. Moving into the new year, these leaders will ensure the organizational focus, strategies, and plans are aligned to accelerate HBA’s mission and support our vision.
We are proud to announce the 2025 HBA Global Board of Directors:
Executive Committee:
- Chair: Tamika Jean-Baptiste, Amgen
- Vice Chair: Nicola Greenway, Takeda
- Secretary/Treasurer: Marie-Caroline Chauvet, Insigniam
- HBA CEO: Mary Stutts*
Directors at Large:
- Tanya Alcorn, Pfizer Inc.
- Dianne Auclair Rocha*, Novartis Pharmaceuticals
- Kathryn Becker*, Abbott
- Dr. Deepa Desai, D Cube Consultancy
- Adam Dubow, Day One Biopharmaceuticals
- Sandra Foreo, ZS Associates
- Judy Kannenberg*, Astellas
- Deborah Lancaster, Roche Diagnostics
- Sandra Orta*, BMS
- Wendy Short Bartie, Bristol Myers Squibb
- Preety Sidhu Adler, Cardinal Health
- Victoria Williams, GSK
*non-voting
We are also pleased to announce the 2025 HBA Nominating Committee:
- Chair: Carol Montandon, Quality & Compliance Senior Executive
- Andrea Henderson, DHR Global
- Andrea Loewendorf, UCB
- Kristen Von Seggern, Johnson & Johnson
- Dianne Yurek, Scale Health
-------
The generous donation of time, talent, and expertise from Board members enables the HBA to sustain and evolve our business strategies while maintaining a laser focus on the longer-term goal of gender equity at all levels of leadership around the globe.
As the new Board and Nominating Committee prepare for the year ahead, we also want to graciously thank the 2024 Global Board of Directors and the 2024 Nominating Committee.
A special thank you to leaders completing their appointments:
- Jocelyn Allen, Sanofi
- Paula Bekinschtein, WalkBek Consulting
- Miguel Serrano Kieckenbusch, Compremium AG
- Sabine Hutchison, HBA EMEA Operating Board President; Seuss+
- Nyawira Njeru, Hologic, Inc.
- Karima Sharif, HBA North American Operating Board President; Initiative
- Erik D. Smith, PhD, Deloitte LLP